NeuroOne raises product gross margin outlook to 53% as management highlights new pain management initiatives

Earnings Call Insights: NeuroOne Medical Technologies Corporation (NMTC) Q3 2025

MANAGEMENT VIEW

* CEO David A. Rosa reported "excellent progress in the third quarter of fiscal year 2025 on our financial objectives as well as achieving successful outcomes in treating patients with our OneRF ablation system, advancing our product development programs and strengthening our management team." He emphasized a 105% increase in product revenue to $1.7 million and a rise in product gross margins to 53.9%.
* Rosa highlighted that the company remains debt free and is "funded through at least fiscal year 2026 based on contractual minimum orders expected under our contract with Zimmer Biomet with the potential to get to cash flow breakeven if we achieve some of the key milestones currently in progress." He referenced the April financing of $8.2 million in net proceeds as a major factor supporting this position.
* On the clinical front, Rosa celebrated "our first patient to reach the 1-year of seizure freedom milestone after being treated with our OneRF ablation system." He announced plans to initiate a post-market registry to collect outcomes data for OneRF-treated patients.
* The company is expanding into pain management, with a 510(k) submission to the FDA for trigeminal neuralgia ablation, and is pursuing lower back pain treatment via basivertebral nerve ablation and spinal cord stimulation. Rosa stated, "If cleared by FDA, we expect to either commercialize the product directly or work with a strategic partner. There is the potential to generate revenues from trigeminal nerve ablation late in calendar year 2025, which is not currently factored into our operational plan."
* Rosa announced the company received its "first order from a leading biotech company to test our drug delivery system," marking a step forward for the technology platform's diagnostic and therapeutic capabilities.
* He also highlighted regulatory and intellectual property milestones, including a granted international patent for the spinal cord stimulation electrode and a notice of allowance from the U.S. Patent and Trademark Office.
* Management appointments included Dr. Parag Patil as Chief Medical Adviser and Emily Johns as General Counsel and Corporate Secretary, with Rosa noting "their additions have also brought cost savings."
* CFO Ronald W. McClurg stated, "Product revenue increased 105% to $1.7 million in the third quarter of fiscal 2025 compared to product revenue of $0.8 million in the third quarter of fiscal '24." He added, "Product gross profit increased significantly to $0.9 million 53.9% of revenue in the third quarter of fiscal 2025 compared to product gross profit of $0.3 million or 34.1% of revenue in the same quarter of the prior fiscal year."

OUTLOOK

* The company reiterated its fiscal year 2025 guidance, expecting product revenue to be in the range of $8 million to $10 million, representing an increase of between 132% and 190% over fiscal year 2024. Rosa also increased product gross margin expectations to be between 50% and 53% versus the previous guidance of 47% to 51%. "We are reiterating our fiscal year 2025 guidance and expect product revenue to be in the range of $8 million to $10 million... and we are also increasing our product gross margin expectations to be between 50% and 53% versus our previous guidance of 47% to 51%."
* No forward-looking financial projections were provided for 2026, with McClurg stating, "We are not giving a forecast yet for 2026. We do -- we are confident in the range, but we just have not made that public."

FINANCIAL RESULTS

* Product revenue increased 105% to $1.7 million in the third quarter, and for the first 9 months of fiscal 2025, product revenue was $6.4 million. Licensing revenue totaled $3 million in the first 9 months, derived from the Zimmer Biomet agreement.
* Product gross profit was $0.9 million, or 53.9% of revenue in the third quarter. Operating expenses decreased 9% to $2.8 million, with R&D expense steady at $1.2 million and SG&A expense down to $1.6 million.
* Net loss in the third quarter improved to ($1.5 million) or ($0.03) per share. Cash and cash equivalents as of June 30, 2025, were $8 million, with no debt outstanding.

Q&A

* Jeffrey Scott Cohen, Ladenburg Thalmann: Asked about the AG drug delivery platform and its testing status. Rosa explained that "devices were ordered for initial testing just on the bench. And then from there, assuming that's successful, they will be used in animals. And then ultimately, if the testing is successful in animals, then it would roll into a future clinical trial in humans."
* Cohen asked if the compound itself is cleared. Rosa clarified "That's still in development. So it's not cleared yet. There's not been any human testing done with that, but that will happen."
* Cohen inquired about the marketplace for trigeminal ablation. Rosa responded that there are "about 150,000 people in the U.S. that suffer from this condition" and that the same doctors performing brain ablations are also treating facial pain, making expansion logical.
* Cohen asked about SCS design and product specifics. Rosa stated "there are going to be multiple components to the system. There'll be a delivery system, the electrode itself. So it's likely that there would be much like what you see in brain ablation as well as facial pain multiple SKUs for -- that represents the additional components."
* Cohen requested a Q4 outlook and 2026 guidance. McClurg stated, "We are not giving a forecast yet for 2026."

SENTIMENT ANALYSIS

* Analysts maintained a tone of curiosity and cautious optimism, focusing on pipeline progress, product specifics, and future commercialization potential. Questions centered on technical development and market size, with no overt skepticism.
* Management's tone was confident and upbeat in both prepared remarks and the Q&A, with Rosa highlighting clinical milestones and financial strength. Confidence was evident in statements such as "we are reiterating our fiscal year 2025 guidance" and "we are confident in the range."
* Compared to the previous quarter, the tone remains confident, with continued emphasis on clinical and commercial progress. Analysts' tone is neutral to slightly positive in both quarters.

QUARTER-OVER-QUARTER COMPARISON

* Guidance for product revenue ($8 million to $10 million) was reiterated, but product gross margin expectations increased to 50%-53% from the prior range of 47%-51%.
* Strategic focus expanded to include pain management and drug delivery, supported by new product development efforts and early commercial partnerships.
* Analysts continued to focus on commercial adoption, development timelines, and market opportunities. Management's confidence remained high, with added emphasis on operational execution and pipeline diversification.
* Net loss and cash position both improved quarter-over-quarter, with no debt and a stronger working capital position.

RISKS AND CONCERNS

* Management acknowledged that some revenue-generating opportunities, such as trigeminal nerve ablation, are "not currently factored into our operational plan" and are contingent upon regulatory clearance.
* No explicit new risks or uncertainties were highlighted outside of the company's standard caution regarding forward-looking statements.
* Analyst questions reflected a desire for greater clarity on product development timelines and market sizing, indicating ongoing investor focus on execution risk.

FINAL TAKEAWAY

NeuroOne Medical Technologies Corporation reported robust revenue growth and margin improvements in Q3 2025, driven by success with the OneRF ablation system and disciplined cost control. The company reiterated its product revenue guidance while raising its gross margin outlook, signaling confidence in ongoing operational momentum. Strategic expansion into pain management and drug delivery, bolstered by new management hires and strengthened intellectual property, positions the company for future growth, although near-term revenue from pipeline initiatives remains subject to regulatory milestones and continued execution.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/nmtc/earnings/transcripts]

MORE ON NEUROONE MEDICAL TECHNOLOGIES

* NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4813615-neuroone-medical-technologies-corporation-nmtc-q3-2025-earnings-call-transcript]
* NeuroOne receives allowance for key patent from U.S. Patent & Trademark Office [https://seekingalpha.com/news/4470574-neuroone-receives-allowance-for-key-patent-from-us-patent-trademark-office]
* Seeking Alpha’s Quant Rating on NeuroOne Medical Technologies [https://seekingalpha.com/symbol/NMTC/ratings/quant-ratings]
* Historical earnings data for NeuroOne Medical Technologies [https://seekingalpha.com/symbol/NMTC/earnings]
* Financial information for NeuroOne Medical Technologies [https://seekingalpha.com/symbol/NMTC/income-statement]